Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Net Cash Flow: 2009-2024

Historic Net Cash Flow for Cytokinetics (CYTK) over the last 16 years, with Dec 2024 value amounting to -$18.4 million.

  • Cytokinetics' Net Cash Flow rose 206.19% to $152.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $181.9 million, marking a year-over-year increase of 445.11%. This contributed to the annual value of -$18.4 million for FY2024, which is 139.76% down from last year.
  • Cytokinetics' Net Cash Flow amounted to -$18.4 million in FY2024, which was down 139.76% from $46.2 million recorded in FY2023.
  • In the past 5 years, Cytokinetics' Net Cash Flow ranged from a high of $46.6 million in FY2020 and a low of -$45.5 million during FY2022.
  • Moreover, its 3-year median value for Net Cash Flow was -$18.4 million (2024), whereas its average is -$5.9 million.
  • Its Net Cash Flow has fluctuated over the past 5 years, first spiked by 899.45% in 2020, then slumped by 253.24% in 2022.
  • Over the past 5 years, Cytokinetics' Net Cash Flow (Yearly) stood at $46.6 million in 2020, then crashed by 36.24% to $29.7 million in 2021, then tumbled by 253.24% to -$45.5 million in 2022, then skyrocketed by 201.66% to $46.2 million in 2023, then crashed by 139.76% to -$18.4 million in 2024.